Pre-Therapeutic Dosimetry Employing Scandium-44 for Radiolabeling PSMA-617

E. Eppard
{"title":"Pre-Therapeutic Dosimetry Employing Scandium-44 for Radiolabeling PSMA-617","authors":"E. Eppard","doi":"10.5772/INTECHOPEN.79157","DOIUrl":null,"url":null,"abstract":"In recent years, the positron emitter scandium-44 moved into the focus of research pro- viding favorable nuclide properties for an application in nuclear medicine. Radiolabeling of PSMA-617 with scandium-44 as diagnostic match for [ 177 Lu]Lu-PSMA-617 instead of gallium-68 would enable pre-therapeutic dosimetry in clinical setting. Due to the chemical similarities of scandium and lutetium, the in vitro and in vivo characteristics of [ 177 Lu]Lu-PSMA-617 are more similar to [ 44 Sc]Sc-PSMA-617 than to the 68 Ga-compounds [ 68 Ga]Ga-PSMA-617 or [ 68 Ga]Ga-PSMA-11. [ 44 Sc]Sc-PSMA-617 showed its potential in a clinical setting as a PET imaging agent of prostate cancer providing several advan- tages over gallium-68 labeled tracers. The longer half-life of the nuclide would allow, for example, an optimized patient management and treatment, long-term or late time point imaging as well as transportation to more distant PET centers. However, especially clinical applications like individual dosimetry or intraoperative applications are still under investigation.","PeriodicalId":20788,"journal":{"name":"Prostatectomy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostatectomy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5772/INTECHOPEN.79157","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

In recent years, the positron emitter scandium-44 moved into the focus of research pro- viding favorable nuclide properties for an application in nuclear medicine. Radiolabeling of PSMA-617 with scandium-44 as diagnostic match for [ 177 Lu]Lu-PSMA-617 instead of gallium-68 would enable pre-therapeutic dosimetry in clinical setting. Due to the chemical similarities of scandium and lutetium, the in vitro and in vivo characteristics of [ 177 Lu]Lu-PSMA-617 are more similar to [ 44 Sc]Sc-PSMA-617 than to the 68 Ga-compounds [ 68 Ga]Ga-PSMA-617 or [ 68 Ga]Ga-PSMA-11. [ 44 Sc]Sc-PSMA-617 showed its potential in a clinical setting as a PET imaging agent of prostate cancer providing several advan- tages over gallium-68 labeled tracers. The longer half-life of the nuclide would allow, for example, an optimized patient management and treatment, long-term or late time point imaging as well as transportation to more distant PET centers. However, especially clinical applications like individual dosimetry or intraoperative applications are still under investigation.
使用钪-44放射标记PSMA-617的治疗前剂量测定
近年来,正电子发射体钪-44成为研究的热点,为核医学的应用提供了良好的核素性质。用钪-44代替镓-68对PSMA-617进行放射性标记,作为[177 Lu]Lu-PSMA-617的诊断匹配,可以在临床环境中进行治疗前剂量测定。由于钪和镥的化学相似性,[177 Lu]Lu- psma -617的体内外特性更接近于[44 Sc]Sc- psma -617,而不是68 Ga化合物[68 Ga]Ga- psma -617或[68 Ga]Ga- psma -11。[44 Sc]Sc- psma -617显示了其作为前列腺癌PET显像剂的临床潜力,与镓-68标记的示踪剂相比,它具有几个优势。核素较长的半衰期将允许,例如,优化患者管理和治疗,长期或晚时间点成像以及运输到更远的PET中心。然而,特别是临床应用,如个体剂量测定或术中应用仍在研究中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信